Abstract
CDK6 is a pivotal kinase in cell cycle progression and has been targeted in many cancers and degenerative diseases. Fisetin, a potent flavonol inhibitor of CDK6, was modified in silico to develop better CDK6 inhibitor(s). Molecular docking studies were performed with in silico-derived fisetin derivatives. All fisetin derivatives were capable of being CDK6 inhibitors; two of them had improved binding characteristics compared to fisetin. Molecular docking studies were executed in the presence of dexamethasone, a commonly administered corticosteroid. These two derivatives showed a stronger binding affinity with CDK6 in the presence of dexamethasone. Two fisetin derivatives had a thermodynamically favorable interaction with CDK6 compared to fisetin and had equivalent ADME properties, and would be well tolerated by the body. This study holds immense potential for developing new flavonoid drugs for cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
